Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Total Debt (2020 - 2023)

Kiora Pharmaceuticals (KPRX) has disclosed Total Debt for 5 consecutive years, with $495000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Total Debt rose 57.79% year-over-year to $495000.0, compared with a TTM value of $495000.0 through Sep 2023, up 57.79%, and an annual FY2020 reading of $278190.0, changed N/A over the prior year.
  • Total Debt was $495000.0 for Q3 2023 at Kiora Pharmaceuticals, up from $313853.0 in the prior quarter.
  • Across five years, Total Debt topped out at $495000.0 in Q3 2023 and bottomed at $278190.0 in Q2 2020.
  • Average Total Debt over 4 years is $314438.1, with a median of $297877.5 recorded in 2022.
  • Peak annual rise in Total Debt hit 57.79% in 2023, while the deepest fall reached 3.99% in 2023.
  • Year by year, Total Debt stood at $278190.0 in 2020, then changed by 0.0% to $278190.0 in 2021, then grew by 12.77% to $313714.0 in 2022, then surged by 57.79% to $495000.0 in 2023.
  • Business Quant data shows Total Debt for KPRX at $495000.0 in Q3 2023, $313853.0 in Q2 2023, and $313299.0 in Q1 2023.